1. Unraveling Clinical Developments in NASH

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Educational Series on NASH

4. Pathogenesis of NASH Moving Past the 2-Hit Hypothesis

5. Substrate Overload Lipotoxic Liver Injury (NASH)

6. Substrate Overload Lipotoxic Liver Injury (NASH) (cont)

7. Substrate Overload Lipotoxic Liver Injury (NASH) (cont)

8. Substrate Overload Lipotoxic Liver Injury (NASH) (cont)

9. Substrate Overload Lipotoxic Liver Injury (NASH) (cont)

10. Substrate Overload Lipotoxic Liver Injury (NASH) (cont)

11. The Fates of Fatty Acids

12. Targets of Therapy

13. Importance of Understanding Pathogenesis

14. CVC Phase 2b Trial CENTAUR Study

15. CVC Phase 2b Trial Results

16. ELF MOA

17. ELF Phase 2 Trial GOLDEN Trial

18. ELF Phase 2 Trial GOLDEN Trial Results

19. OCA Phase 2b Trial FLINT Trial

20. OCA Phase 2b Trial FLINT Trial Results

21. OCA Phase 2b Trial Pruritis and Cholesterol

22. Limitations of Current Phase 3 Trials in NASH Importance of Surrogate Endpoints

23. Selonsertib MOA

24. Selonsertib Phase 2 Trial Trial Design

25. Selonsertib Phase 2 Trial Trial Results

26. Assessment of Selonsertib Phase 2 Trial Results and Design

27. Current Treatment Strategies for NASH

28. Current Treatment Strategies for NASH (cont)

29. Concluding Remarks

30. Abbreviations

31. Abbreviations (cont)

32. Abbreviations (cont)